MOVEMENT DISORDERS SOCIETY 20th INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS 2016 - BERLIN, GERMANY, JUNE 19-23, 2016
Disease Severity is Not Predictive of the Dose Required for Apomorphine Sublingual Film (APL-130277) to Convert a Patient with Parkinson's Disease from OFF to Fully ON
Holly Shill, MD, Eric J. Pappert, MD, Albert Agro, PhD, Bruce Dzyngel, BSc (Hons), Thierry Bilbault, PhD, Stuart Isaacson, MD, Robert A. Hauser, MD
Download .pdf
Treatment of OFF Episodes in Parkinson's Disease: An Evaluation of Patient and Caregiver Insights
Eric J. Pappert, MD, Nigel deGruyther, B.Sc.Pharm, MBA, Albert Agro, PhD
Download .pdf
Treatment of OFF Episodes in Parkinson's Disease: An Evaluation of Physician Insights
Eric J. Pappert, MD, Albert Agro, PhD, Nigel deGruyther, B.Sc.Pharm, MBA
Download .pdf
Oral Apomorphine Film (APL-130277) Produces No Buccal Mucosal Irritation: Results from a 28-Day Toxicology Study in Hamsters
Albert Agro, PhD, Eric J. Pappert, MD, Bruce Dzyngel, BSc (Hons), Thierry Bilbault, PhD, Simon Taylor, BSc, Robin Walker, PhD
Download .pdf
The Efficacy of Apomorphine Sublingual Film (APL-130277) to Turn a Patient with Parkinson's Disease from an OFF State to a Full ON State by Demographics and Baseline Characteristics
Holly Shill, MD, Eric J. Pappert, MD, Albert Agro, PhD, Bruce Dzyngel, BSc (Hons), Thierry Bilbault, PhD, Robert A. Hauser, MD, Stuart Isaacson, MD
Download .pdf
Pharmacokinetic-Pharmacodynamic Effects of Apomorphine Sublingual Film (APL-130277) for the Rapid Management of OFF Episodes in Patients with Parkinson's Disease
Eric J. Pappert, MD, Bruce Dzyngel, BSc (Hons), Thierry Bilbault, PhD, Albert Agro, PhD
Download .pdf
Minimum MDS-UPDRS Part III Change Needed to Convert a Patient with Parkinson's Disease from the OFF to Full ON State with Apomorphine Sublingual Film (APL-130277)
Holly Shill, MD, Eric J. Pappert, MD, Bruce Dzyngel, BSc (Hons), Albert Agro, PhD, Thierry Bilbault, PhD, Stuart Isaacson, MD, Robert A. Hauser, MD
Download .pdf
EUROPEAN ACADEMY OF NEUROLOGY 2ND CONGRESS – COPENHAGEN, DENMARK, MAY 28-31 2016
The Treatment of OFF Episodes in Parkinson’s Disease: An Evaluation of Patient and Caregiver Insights
Eric J. Pappert, MD, Nigel deGruyther, BScPharm, MBA, Albert Agro, PhD
Download .pdf
The Treatment of OFF Episodes in Parkinson’s Disease: An Evaluation of Physician Practices
Eric J. Pappert, MD, Albert Agro, PhD, Nigel deGruyther, BScPharm, MBA
Download .pdf
Apomorphine Film (APL-130277) Produces No Buccal Mucosal Irritation: Results from a 28-Day Toxicology Study in Hamsters
Eric J. Pappert, MD, Bruce Dyzngel, Thierry Bilbault, PhD, Albert Agro, PhD, Simon Taylor, PhD, Robin Walker, PhD
Download .pdf
AMERICAN ACADEMY OF NEUROLOGY 68TH ANNUAL MEETING - VANCOUVER CANADA APRIL 15-21 2016
Efficacy of Sublingual Apomorphine Film Strip (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Robert Hauser, Bruce Dzyngel, Thierry Bilbault, PhD, Holly Shill, MD, Albert Agro, PhD
Download .pdf
Safety of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson's disease
Stuart Isaacson, MD, Eric J. Pappert, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Albert Agro, PhD
Download .pdf
The Effects of Sublingual Apomorphine (APL-130277) by Disease Severity on the Acute Management of OFF Episodes in Parkinson's Disease
Holly Shill, MD, Eric J. Pappert, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Albert Agro, PhD
Download .pdf
XXI WORLD CONGRESS ON PARKINSONS DISEASE AND RELATED DISORDERS - MILAN, ITALY, DECEMBER 6-9, 2015
Efficacy of sublingual apomorphine film strip (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease
Stuart Isaacson, MD, Albert Agro, PhD, Jordan Dubow, MD Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo, Holly Shill, MD, Robert A. Hauser, MD Download .pdf
Safety of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease
Albert Agro, PhD, Jordan Dubow, MD, Bruce Dzyngel Thierry Bilbault, PhD, Anthony Giovinazzo, Stuart Isaacson, MD
Download .pdf
The effects of sublingual apomorphine (APL-130277) by disease characteristics on the acute management of OFF episodes in Parkinson’s disease
Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo, Albert Agro, PhD
Download .pdf
Baseline disease severity not predictive of sublingual apomorphine (APL-130277) dose needed to convert a PD patient from the OFF to ON state
Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo, Albert Agro, PhD
Download .pdf
Minimum MDS-UPDRS Part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with sublingual apomorphine (APL-130277)
Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo, Albert Agro, PhD
Download .pdf
AMERICAN NEUROLOGICAL ASSOCIATION 140th ANNUAL MEETING - CHICAGO, IL, SEPTEMBER 27-29, 2015
Pharmacokinetics, safety and tolerability of sub-lingually administered APL-130277 compared to subcutaneous apomorphine in healthy volunteers
Albert Agro, PhD, Jordan Dubow, MD, Lee Toong-Chow, PhD and Anthony Giovinazzo (Abstract S402). Annals of Neurology. 2015;78(Issue S19):S44.
Download .pdf
Efficacy of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease
Robert A Hauser, MD, Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo and Albert Agro, PhD (Abstract S403): Annals of Neurology. 2015;78(Issue S19):S44.
Download .pdf
Safety of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease
Stuart Isaacson, MD, Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo and Albert Agro, PhD (Abstract S415). Annals of Neurology. 2015;78(Issue S19):S47.
Download .pdf
Pharmacokinetic-Pharmacodynamic effects of sublingual apomorphine (APL-130277) for acute rescue of OFF episodes in Parkinson’s disease patients
Jordan Dubow, MD; Bruce Dzyngel; Thierry Bilbault, PhD; Anthony Giovinazzo; Albert Agro, PhD (Abstract S416). Annals of Neurology. 2015;78(Issue S19):S48-49.
Download .pdf
Pharmacokinetic-pharmacodynamic Effects of Sublingual Apomorphine (APL-130277) for the Acute Management of OFF Episodes in Parkinson’s Disease Patients
Jordan Dubow, MD; Bruce Dzyngel; Thierry Bilbault, PhD; Anthony Giovinazzo; Albert Agro, PhD
Download .pdf
EUROPEAN ACADEMY OF NEUROLOGY 1ST CONGRESS - BERLIN, GERMANY, JUNE 20-23 2015
Efficacy of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease
Robert A Hauser, MD, Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo and Albert Agro, PhD (Abstract P2153). European Journal of Neurology. 2015;22(Suppl 1):249.
Download .pdf
Safety of sublingual APL-130277 for the treatment of OFF episodes in patients with Parkinson's disease
Stuart Isaacson, MD, Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo and Albert Agro, PhD (Abstract P2154). European Journal of Neurology. 2015;22(Suppl 1):250.
Download .pdf
MOVEMENT DISORDERS SOCIETY 19TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 2015 – SAN DIEGO, CA, JUNE 14-18, 2015
Pharmacokinetics, safety and tolerability of sub-lingually administered APL-130277 compared to subcutaneous apomorphine in healthy volunteers
Albert Agro, PhD, Jordan Dubow, MD, Lee Toong-Chow, PhD and Anthony Giovinazzo (Abstract #170). Movement Disorders. 2015;30(Suppl 1):S64-65.
Download .pdf
Pharmacokinetics, safety and tolerability of high-dose sub-lingually administered APL-130277 in healthy volunteers
Albert Agro, PhD, Jordan Dubow, MD, Lee Toong-Chow, PhD and Anthony Giovinazzo (Abstract #171). Movement Disorders. 2015;30(Suppl 1):S65-66.
Download .pdf
Efficacy of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease
Robert A Hauser, MD, Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo and Albert Agro, PhD (Abstract #233). Movement Disorders. 2015;30(Suppl 1):S90.
Download .pdf
Safety of sublingual APL-130277 for the treatment of OFF episodes in patients with Parkinson's disease
Stuart Isaacson, MD, Jordan Dubow, MD, Bruce Dzyngel, Thierry Bilbault, PhD, Anthony Giovinazzo and Albert Agro, PhD (Abstract #243). Movement Disorders. 2015;30(Suppl 1):S94-95.
Download .pdf
